Bio-Rad Reports Q4 & FY25 Results with Impairment Charge, Declining Non-GAAP EPS, and Modest 2026 Outlook

summarizeSummary

Bio-Rad Laboratories reported a $172.8 million impairment charge, a decline in non-GAAP diluted EPS and operating margins for Q4 and full-year 2025, alongside a modest revenue growth outlook for 2026.

check_boxKey Events

• Material Impairment Charge Recorded

  The company recognized a $172.8 million impairment of purchased intangibles and related items in Q4 2025, significantly impacting GAAP operating income.

• Non-GAAP Profitability Declined

  Non-GAAP diluted EPS decreased to $2.51 in Q4 2025 from $2.90 in Q4 2024, and to $9.92 for full-year 2025 from $10.31 in 2024. Non-GAAP gross and operating margins also compressed.

• Modest Revenue Growth and Segment Weakness

  Full-year 2025 currency-neutral revenue was essentially flat (-0.1%). The Life Science segment experienced a currency-neutral decline of 4.0% in Q4 and 1.3% for the full year, attributed to constrained academic research and biotech funding.

• Subdued 2026 Financial Outlook

  Bio-Rad forecasts non-GAAP currency-neutral revenue growth of only 0.5% to 1.5% and an operating margin of 12.0% to 12.5% for full-year 2026, indicating continued modest growth expectations.

auto_awesomeAnalysis

Bio-Rad Laboratories reported a challenging year with declining non-GAAP profitability and an impairment charge, signaling operational headwinds. While GAAP net income was significantly boosted by a non-operating revaluation of an equity investment, the core business performance, as reflected in non-GAAP metrics, showed a decrease in diluted EPS and compressed margins. The Life Science segment faced particular weakness due to funding constraints. The modest revenue growth outlook for 2026 suggests that these challenges are expected to persist. Investors should focus on the company's ability to improve operational efficiency and drive growth in its core segments, especially given the material impairment charge and the subdued guidance.